Core Insights - Analysts project ResMed's quarterly earnings to be 1.21 billion, marking a 7.5% increase from the same quarter last year [5] Revenue Estimates - The estimated revenue for 'U.S., Canada, and Latin America - Devices' is 118.76 million, showing a 10.6% increase from the year-ago quarter [3] - The total revenue for 'U.S., Canada, and Latin America' is estimated at 646.02 million, suggesting a 7.2% increase year over year [6] - 'U.S., Canada, and Latin America - Masks' is forecasted to reach 1.07 billion, representing an 8.6% increase from the year-ago quarter [9] - 'Combined Europe, Asia, and other markets - Devices' is projected to be 152.24 million, indicating a 9.8% increase from the prior-year quarter [13] - 'Combined Europe, Asia, and other markets - Total Sleep and Respiratory Care' is estimated at 422.09 million, reflecting a 10.8% increase from the year-ago quarter [15] Analyst Revisions - Over the past 30 days, the consensus EPS estimate has been adjusted upward by 0.2%, indicating a reassessment of projections by covering analysts [11] - Analysts emphasize that understanding key metrics beyond consensus earnings and revenue estimates can provide a more comprehensive view of business performance [12] Market Performance - ResMed shares have increased by 2.9% over the past month, contrasting with a -0.2% change in the Zacks S&P 500 composite [16]
Seeking Clues to ResMed (RMD) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics